Prescription Medicines
Lucetin Cap.
- Product Category
- SSRI antidepressant with excellent selectivity and low side effects
- Active Ingredients
- Fluoxetine hydrochloride
- Appearance
- A hard capsule filled with white and gray powder, green at the top and light yellow at the bottom.
- Reimbursement Code
- 648100580
01 / 02
1. Composition and Strength
- Active ingredient: Fluoxetine hydrochloride (USP) 22.4mg (20.0mg as fluoxetine)
- Additives (tar coloring): Blue No. 1
- Other additives: magnesium stearate, citric acid hydrate, corn starch, sodium starch glycolate, capsule, D-mannitol
2. Effectiveness
1. Depression
The drug's effectiveness was seen within 5 to 6 weeks in the treatment of outpatients with depression diagnosed as very similar to DSM-III category depression. Depression is a persistent state of depression or malaise (almost daily for at least two weeks) that is usually significant enough to interfere with daily functioning and must include at least four of the following eight symptoms: changes in appetite, changes in sleep, psychomotor irritability or fatigue, lack of interest in daily life or decreased sexual desire, increased fatigue, feelings of guilt or worthlessness, slowed thinking or difficulty concentrating, and suicide attempts or thoughts of suicide.
The antidepressant effect of this drug on hospitalized depressed patients has not been adequately studied so far, and its effectiveness for long-term administration over 5 to 6 weeks has not been systematically evaluated through controlled trials. Therefore, its usefulness for individual patients is regularly reevaluated when administered long-term.
2. Bulimia nervosa
This drug showed a significant reduction in gluttony and binge-seeking behavior compared to the placebo group. The effectiveness of this drug for long-term administration over 16 weeks has not been systematically evaluated through controlled trials, so its usefulness for individual patients must be regularly reevaluated during long-term administration.
3. Obsessive-compulsive disorder
This drug significantly reduced symptoms of obsessive-compulsive disorder in a double-blind, placebo-controlled clinical trial. To suddenly experience obsessions or compulsions that become quite distressing, time-consuming, or significantly disrupt a person's social or work life. The effectiveness of this drug for long-term administration over 13 weeks has not been systematically evaluated through controlled trials, so its usefulness for individual patients must be regularly reevaluated during long-term administration.
4. Premenstrual dysphoric disorder
Premenstrual dysphoria symptoms, such as depression, anxiety, and emotional instability, appear periodically (the last week of the luteal phase in the menstrual cycle) and disappear within a few days when menstruation begins. These symptoms interfere with social roles and job performance and are accompanied by physical symptoms such as breast pain, headache, joint or muscle pain, abdominal bloating, and weight gain. General premenstrual tension and periodic mental disorders due to antidepressant treatment are excluded from premenstrual dysphoria symptoms. The effectiveness of this drug when used for long periods of more than 6 months has not yet been systematically evaluated. Therefore, doctors who plan to use this drug for a long period of time should regularly re-evaluate the effectiveness of long-term use for each patient.
3. Dosage and dosage
- Adult
1. Depression
1) Initial treatment: The initial dose is fluoxetine hydrochloride, 20 mg orally once a day in the morning.
In controlled clinical trials, doses of 20 to 80 mg per day were administered. If no improvement is observed, an increase in dose may be considered after a few weeks. Doses exceeding 20 mg per day should be administered twice a day (morning and noon) and the maximum dose of 80 mg per day should not be exceeded. The onset of sufficient antidepressant effects may be delayed until 4 weeks or more after treatment.
2) Maintenance/continuing/extended treatment: Although there is no clear data on how long a patient should be treated with this drug, it is recognized among psychopharmacologists that acute signs of depression require drug treatment for several months or more. It is not known whether the amount of antidepressant medication needed to relieve symptoms is the same as the amount needed to maintain or sustain stability.
2. Bulimia nervosa
This drug is administered at 60 mg per day. The daily dosage does not exceed 80 mg.
Measure electrolyte concentrations before starting treatment.
3. Obsessive-compulsive disorder
This drug is administered in doses of 20 to 60 mg per day. The daily dosage does not exceed 80 mg.
4. Premenstrual dysphoric disorder
This drug is administered at 20 mg per day.
After 6 months of treatment, re-evaluate whether continued treatment is necessary.
- Patients with kidney and/or liver damage, patients receiving multiple medications, the elderly, and patients with concomitant diseases: Administer a lower dose or reduce the frequency of administration. Increase or decrease appropriately depending on age and symptoms.
- Related to switching to MAO inhibitors to treat mental illness
When discontinuing treatment with an MAO inhibitor for the treatment of mental illness and starting treatment with the same drug, there must be an interval of at least 14 days. Conversely, before starting treatment with an MAO inhibitor for the treatment of mental illness, at least 5 weeks must elapse after discontinuation of the drug.
- Other MAO inhibitors such as linezolid or methylene blue
Patients receiving linezolid or intravenous methylene blue products should not begin treatment with these products due to the increased risk of serotonin syndrome. Administration should be considered in patients requiring hospitalization, other interventional procedures, or treatment of more urgent psychiatric conditions.
There may be a need to urgently administer linezolid or intravenous methylene blue to patients who are already receiving this medication. If there is no alternative drug to linezolid or intravenous methylene blue and the benefit of treatment with linezolid or intravenous methylene blue is judged to outweigh the risk of serotonin syndrome in a specific patient, the medication should be discontinued immediately and linezolid or intravenous methylene blue should be administered immediately. The preparation can be administered. Patients should be monitored for symptoms of serotonin syndrome for 5 weeks after receiving linezolid or intravenous methylene blue products or 24 hours after the last dose, whichever comes first. Treatment with linezolid or intravenous methylene blue can be restarted 24 hours after the last dose.
The risk of administering methylene blue preparation non-intravenously (oral tablet or local injection) or injecting less than 1 mg/kg intravenously is not clear. Nevertheless, clinicians should be aware of the potential for emergent symptoms of serotonin syndrome with this use.
4. Precautions for use
1. Warning
- Suicidality and antidepressants
In short-term studies of children, adolescents, and young adults (ages 18 to 24) with major depression or other psychiatric disorders, it has been reported that antidepressants increase the risk of suicidal thoughts and behaviors (suicidality) compared to placebo. Physicians considering administering this drug or other antidepressants to children, adolescents, or young adults should always carefully consider whether the clinical need outweighs the risks. In short-term studies, antidepressants did not increase the risk of suicidality compared with placebo in adults over 25 years of age, and this risk was reduced with antidepressants compared to placebo in adults over 65 years of age. Depression and other psychiatric disorders themselves are associated with an increased risk of suicide. Patients of any age starting treatment with antidepressants should be appropriately monitored and carefully observed for worsening disease, suicidal tendencies, or changes in other abnormal behaviors such as hostility, aggression, or anger. The patient's family or guardian is also instructed to observe the patient carefully and contact the doctor if necessary. This drug is not approved for use in children and adolescents.
2. Do not administer to the following patients
1) Patients with a history of hypersensitivity to this drug or its additives
2) Patients with severe renal impairment (glomerular filtration rate <10 mL/min)
3) Patients taking MAO inhibitors
: Co-administration of this drug and MAO inhibitors for the treatment of mental illness or administration of MAO inhibitors within 5 weeks after discontinuation of this drug is contraindicated because it increases the risk of serotonin syndrome. It is also contraindicated to administer this drug within 14 days of discontinuing treatment with MAO inhibitors for the treatment of mental disorders. (Refer to the Usage/Dosage section and 5. General Precautions section)
Starting treatment with this drug in patients receiving MAO inhibitors such as linezolid or intravenous methylene blue is also contraindicated due to the increased risk of serotonin syndrome (see Dosage and Administration section and 5. General Precautions).
3. Administer with caution to the following patients:
1) Seizures: Antidepressants have a potential risk of seizures. Therefore, like other antidepressants, this drug should be used with caution in patients with a history of seizures, and treatment should be discontinued if seizures appear or the number of seizures increases. This drug should be avoided in patients with unstable seizure disorders/epilepsy and should be carefully monitored in patients with controlled epilepsy.
2) Patients with a predisposition to suicide: Depression is associated with an increased risk of suicidal impulses, self-harm, and suicide (cases associated with suicide). This risk persists until depression is significantly reduced. Symptoms may not improve during the first few weeks or longer of treatment, so patients should be closely observed until improvement occurs. General clinical experience shows that the risk of suicide may increase in the early stages of recovery.
Other psychiatric conditions for which this drug is prescribed may also be associated with an increased risk of suicide-related events. These conditions may accompany major depressive disorder. The same precautions as when treating patients with major depressive disorder should be observed when treating patients with other mental disorders. Patients who have had significant suicidal thoughts and a history of suicide before starting treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and such patients should be carefully observed during treatment.
A meta-analysis of placebo-controlled clinical trials of antidepressants in adult patients with mental illness found an increased risk of suicidal behavior with antidepressant use compared with placebo in patients younger than 25 years. Close supervision of patients, especially those at high risk, should be performed while administering drug therapy, especially at the time of initial treatment and after dose changes.
Patients and caregivers should be informed of the need to monitor for clinical worsening, suicidal behavior or impulses, and unusual changes in behavior. They should seek medical attention immediately if these symptoms occur.
3) Mania: Antidepressants should be used with caution in patients with a history of mania or hypomania. As with other antidepressants, this drug should be discontinued in patients who enter a manic period.
4) Cardiovascular effects: As a result of post-marketing surveillance, ventricular arrhythmias including QT interval prolongation and torsade de pointes were reported (see Adverse Reactions, Interactions, and Treatment in Case of Overdose). Fluoxetine should be used with caution in patients with congenital long QT syndrome, a family history of QT interval prolongation, or clinical conditions predisposing to arrhythmias (e.g., hypokalemia, hypomagnesemia, bradycardia, and acute myocardial infarction or uncompensated heart failure), or in patients with increased exposure to this drug (e.g., patients with hepatic impairment). In patients with stable heart disease, an electrocardiogram should be considered before starting treatment with this drug. If signs of cardiac arrhythmia appear during treatment with this drug, treatment should be discontinued and an electrocardiogram should be measured.
5) Patients with hepatic/renal impairment: This drug is extensively metabolized in the liver and excreted through the kidneys. Lower doses (e.g., taken every other day) are recommended for patients with significant hepatic dysfunction. When patients with severe renal impairment (GFR <10 ml/min) requiring dialysis were treated with 20 mg/day of this drug for two months, there was no difference in plasma levels of fluoxetine or norfluoxetine compared to controls with normal renal function.
6) Patients with diabetes: In diabetic patients, blood sugar control may change with the administration of SSRIs. Hypoglycemia occurred during treatment with this drug, and hyperglycemia occurred after discontinuation. Dosage adjustments of insulin and/or oral hypoglycemic agents may be necessary to control blood sugar.
7) Pupil dilation: Pupil dilation has been reported associated with this drug. Therefore, it should be used with caution in patients with increased intraocular pressure or at risk of acute narrow-angle glaucoma.
4. Adverse reactions
1) The most commonly reported adverse reactions when administering fluoxetine are headache, nausea, insomnia, fatigue, and diarrhea. The following table shows adverse reactions observed in clinical trials (9,297 people) and spontaneous reports.
Frequency assessment: very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1,000, <1/100), rare (≥1/10,000, <1/1,000), very rare (<1/10,000), frequency unknown.
(Table. Refer to attached document)
1 Including loss of appetite
2 Includes early morning waking or early and moderate insomnia
3 nightmares included
4 Including loss of sexual desire
Includes 5-sex frigidity
6 Includes hypersomnia and sedation
7 Includes hot flashes
8 Includes erythema, exfoliative rash, heat rash, rash, erythematous rash, follicular rash, generalized rash, macular rash, maculo-papular rash, measlesoid rash, papular rash, itchy rash, bullous rash, and umbilical rash.
9 Including frequent urination
10 Includes ejaculation failure, ejaculation disorder, premature ejaculation, delayed ejaculation, and retrograde ejaculation
11 Includes cervical bleeding, uterine dysfunction, uterine bleeding, genital bleeding, functional uterine bleeding, menorrhagia, frequent menstruation, postmenopausal bleeding, vaginal bleeding
12 Including asthenia
13 May progress to Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (Lyell syndrome)
14 This symptom may be caused by an underlying disease
15 The most frequently occurring include gum bleeding, hematemesis, hematochezia, rectal bleeding, bloody diarrhea, melena, and gastric ulcer bleeding.
16 In post-marketing experience, cases of persistent sexual dysfunction symptoms when discontinuing treatment with this drug have been reported in very rare cases.
2) Suicidal tendency: Increased suicidal tendency in children, adolescents, and young adults (18-24 years old): Cases of suicidal ideation and suicidal behavior have been reported during fluoxetine treatment or in the early stages of discontinuation of fluoxetine treatment (see Warning section 1).
3) Fracture: An epidemiological study conducted mainly on patients over 50 years of age showed that the risk of fracture increased in patients taking SSRIs and TCAs. The mechanism of this risk has not been identified.
4) Withdrawal symptoms that appear when discontinuing fluoxetine administration: Withdrawal symptoms commonly appear when discontinuing fluoxetine administration. The most commonly reported reactions are dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and violent dreams), asthenia, agitation or anxiety, nausea and/or vomiting, tremors, and headache. Typically, these events were mild to moderate and self-limiting, but in some patients they were severe and/or persistent. Therefore, if this drug is no longer needed, the drug should be gradually discontinued by reducing the dose.
5) Rash and allergic reactions: Rash, anaphylactoid reactions and progressive systemic reactions, sometimes severe (involving the skin, kidneys, liver or lungs) have been reported. If rash or other allergic symptoms for which no other etiology can be identified appear, administration of this drug should be discontinued.
6) Weight loss: Weight loss may occur in patients taking this drug, but is generally proportional to baseline body weight.
7) Children and adolescents: In pediatric clinical trials, suicide-related behaviors (suicide attempts and suicidal impulses) and hostility were more commonly observed in children and adolescents administered antidepressants compared to the placebo group. In pediatric clinical trials, manic reactions including mania and hypomania were reported (fluoxetine group: 2.6%, placebo group: 0%), and most of the cases were discontinued. These patients had no previous episodes of hypomania or mania.
After 19 weeks of treatment, pediatric patients who received fluoxetine in clinical trials showed 1.1 cm (1.0 cm vs 2.1 cm, p = 0.004) lower height and 1.1 kg (1.2 kg vs 2.3 kg, p = 0.008) lower body weight compared to the placebo group, and cases of growth retardation were also reported in clinical use. Administration of fluoxetine was associated with a decrease in alkaline phosphatase levels.
It has not been established whether the height and weight loss observed in the 19-week clinical trial affects the ability to reach normal adult height. In addition, adverse reactions indicating potential delayed sexual maturation or sexual dysfunction have been reported from clinical use in children, and since the possibility of delayed puberty cannot be ruled out, growth and pubertal development (height, weight, tanner stage) should be observed during and after administration of this drug. If any developmental delays are observed, consultation with a pediatrician should be considered. The safety of fluoxetine for long-term administration over 19 weeks has not been systematically evaluated.
8) Hyponatremia: Hyponatremia (serum sodium concentration below 110 mmol/l in some cases) has been reported. Hyponatremia appeared to resolve when treatment with this drug was discontinued. These cases are complex with varying possible etiologies, but some may be attributed to syndrome of abnormal antidiuretic hormone secretion (SIADH). Most of these cases occurred in elderly patients, patients taking diuretics, or patients with volume deficiency.
9) Platelet function: Changes in platelet function and/or abnormal results through laboratory tests have been rarely reported in patients receiving this drug. There have been reports of abnormal bleeding in several patients receiving this drug, but it is unclear whether this effect was caused by the drug.
10) Post-marketing surveillance
Following approval of this drug, the following adverse reactions were identified: Because these reactions were voluntarily reported from a patient population of unspecified size, it is difficult to determine whether the frequency is reliable or the causal relationship with drug exposure. Adverse reactions temporally related to this drug administered after marketing, and voluntarily reported adverse reactions that may not be causally related to the drug, are as follows:
Aplastic anemia, atrial fibrillation1, cataract, cerebrovascular accident1, cholestatic jaundice, dyskinesia (for example, in a 77-year-old female patient who received this drug for 5 weeks, chewing syndrome of the cheek and tongue due to involuntary tongue protrusion completely disappeared within a few months after stopping the drug), eosinophilic pneumonia, epithelial necrosis, erythema multiforme, erythema nodosum, exfoliative dermatitis, Gynecomastia, cardiac arrest1, liver failure/necrosis, hyperprolactinemia, hypoglycemia, immune-related hemolytic anemia, renal failure, movement disorders and exacerbation of existing movement disorders in patients with risk factors including drugs associated with these reactions, optic neuritis, pancreatitis1, pancytopenia, pulmonary embolism, pulmonary hypertension1, QT prolongation, Stevenson-Johnson syndrome, thrombocytopenia1, thrombocytopenic purpura, Ventricular tachycardia (including torsades de pointes type arrhythmia), vaginal bleeding, aggressive behavior1.
1 These terms represent serious adverse events but do not meet the definition of adverse events. These reactions are included here because of their severity.
5. General precautions
1) Long half-life of this drug and its metabolites: Due to the long half-life of this drug (2-3 days) and its main metabolite (7-9 days), changes in dosage are not fully reflected for several weeks, which also affects the determination of the final dose and termination of treatment. (Refer to the Dosage and Administration section)
2) Interference with cognition and motor performance: Like other psychotropic drugs, this drug may impair judgment, thinking, or motor function, so patients should be cautious when operating dangerous machinery, such as driving a car, until they are reasonably sure that performance will not be affected.
3) Use of concomitant drugs or alcohol: Patients should seek advice from their doctor if they are taking or plan to take general or specialty drugs, including alcohol or herbal medicines. You should also seek medical advice if you plan to stop taking any medications while taking Furozac.
4) Physical and mental dependence: Abuse potential, tolerance, and physical dependence have not been systematically studied in animals and humans. Although clinical trials have not revealed withdrawal syndromes or drug-seeking behaviors, these observations are not systematic, and based on this limited experience, it is not possible to predict the extent to which central nervous system-active drugs will be subject to misuse, diversion, or abuse once they become available. Therefore, it is necessary to determine whether the patient has experienced drug abuse in the past, and carefully observe and track whether there are signs of drug abuse or misuse (development of tolerance, increased dosage, drug-seeking behavior).
5) Unlike the treatment of depression, the treatment effect for premenstrual dysphoric disorder appears very quickly, and symptoms generally improve in the first cycle of treatment. Clinical trials have shown that symptoms tend to reappear quickly, usually within 1-2 cycles, after stopping treatment. Before starting treatment for premenstrual dysphoric disorder, patients should be fully informed of the benefits and risks of taking this drug.
6) Patients (adults, children) with major depression, even if taking antidepressants, may experience worsening of depressive symptoms, suicidal thoughts and behaviors (suicidal tendencies), and abnormal behavior changes until the disease shows significant improvement.
7) Suicide is a known risk factor for depression and certain other psychiatric disorders, and these disorders are themselves the strongest predictors of suicide. However, there has been long-standing concern that antidepressants may lead to worsening of depressive symptoms and the development of suicidality in some patients during the early stages of treatment. A pooled analysis of placebo-controlled, short-term clinical trials of antidepressants (SSRIs and others) indicates that these drugs increase the risk of suicidal thoughts and behaviors (suicidality) in children, adolescents, and young adults (18-24 years) with major depression and other psychiatric disorders. In short-term studies, antidepressants did not increase the risk of suicidality compared with placebo in adults over 25 years of age. In adults over 65 years of age, this risk was reduced with antidepressants compared to placebo.
8) A pooled analysis of placebo-controlled clinical trials in children and adolescents with major depression, obsessive-compulsive disorder, or other psychiatric disorders included a total of 24 short-term clinical trials of 9 antidepressants in more than 4,400 patients. The pooled analysis of placebo-controlled clinical trials in adults with major depression and other psychiatric disorders included a total of 295 short-term (median duration: 2 months) clinical trials of 11 antidepressants in more than 77,000 patients. Although there were significant differences in the risk of suicidality among drugs, there was a trend toward increased suicidality in young adults for most all drugs studied. There were differences in the absolute risk of suicidality among different indications, with the highest incidence occurring in major depression. However, the difference in risk (antidepressants vs. placebo) was relatively stable within age groups and between indications. These risk differences (differences between antidepressants and placebo in the number of suicidal tendencies per 1,000 treated patients) are shown in Table 1 below.
(Refer to Table 1 and attached document)
9) Suicide did not occur in any pediatric clinical trials. Suicides occurred in clinical trials in adults, but the numbers were not sufficient to draw any conclusions about the drug's effect on suicide. It is not known whether the risk of suicidality extends to long-term (i.e., more than several months) use of the drug. However, there is ample evidence from ongoing placebo-controlled clinical trials in adults with depression that the use of antidepressants may delay the recurrence of depression.
10) It is unknown whether there is an increase in suicidal tendencies in adults or in patients receiving long-term treatment for more than several months, but patients using antidepressants should be carefully monitored for changes in suicidal tendencies, self-harm, hostility, and any abnormal behavior during the first few months of treatment or when changing the dose (increase or decrease).
11) Patients of all ages using antidepressants may experience anxiety, agitation, panic disorder, insomnia, excitement, hostility, aggression, impulsivity, akathisia, hypomania, and mania. Although the correlation with these symptoms is unclear, caution should be exercised as they may be precursor symptoms of suicidal tendencies. In addition, instruct family members and guardians to monitor these symptoms or suicidal tendencies daily and notify the doctor immediately when symptoms appear.
12) If depressive symptoms continue to worsen, suicidal tendencies appear, or symptoms that may be prodromal symptoms of suicidal tendencies (severe or sudden symptoms, symptoms not originally present in the patient) appear, discontinuation of this drug should be considered.
13) Although not proven in controlled clinical trials, the use of antidepressants during a depressive episode in patients with bipolar disorder may promote manic or manic episodes. Therefore, before administering antidepressants, a detailed psychiatric history, including family history of suicide, bipolar disorder, or depression, should be checked to screen for the possibility of bipolar disorder.
14) Withdrawal symptoms observed when SSRI treatment is discontinued: Withdrawal symptoms are particularly common when treatment is stopped suddenly. In clinical trials, adverse reactions observed upon discontinuation of treatment occurred in approximately 60% of patients in both the acetabine and placebo groups. Of these adverse events, 17% in the ZERO drug group and 12% in the placebo group were serious in nature. The risk of withdrawal symptoms may vary depending on several factors, including treatment duration, dose, and rate of dose reduction. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), asthenia, nervousness or anxiety, nausea and/or vomiting, tremors and headaches are the most commonly reported reactions. Typically, these symptoms are mild to moderate in severity, but may be severe in some patients. These symptoms usually appear within the first few days after stopping treatment. Although in some patients these symptoms may persist (for longer than 2-3 months), symptoms generally heal on their own and usually disappear within 2 weeks. Therefore, depending on the patient's needs, it is recommended to gradually reduce the dose over a period of at least 1-2 weeks when discontinuing treatment. When discontinuing the administration of this drug, patients should be monitored to see if these symptoms appear, and patients or guardians should not unilaterally stop taking this drug without consulting the prescribing doctor. If intolerable symptoms occur due to reduction or discontinuation of treatment, re-administration of the previously prescribed dose may be considered. After that, you can continue to reduce weight more gradually. The risk of symptoms due to discontinuation of this drug can be minimized by gradually reducing plasma fluoxetine and norfluoxetine concentrations until the end of treatment.
15) Bleeding: Abnormal skin bleeding, such as ecchymosis and purpura, has been reported with SSRI drugs. Antidepressants with serotonergic effects may increase the risk of postpartum hemorrhage. Ecchymosis has been uncommonly reported during treatment with this drug. Other bleeding events (vaginal bleeding, gastrointestinal bleeding, and other skin or mucous membrane bleeding) have been rarely reported. Caution is advised in patients with a history of bleeding disorders, as well as those taking SSRIs, anticoagulants, drugs known to affect platelet function (atypical antipsychotics such as clozapine, phenothiazines, most tricyclic antidepressants (TCAs), aspirin, NSAIDS), or other drugs that may increase the risk of bleeding.
16) Akathisia/psychomotor restlessness: Fluoxetine use has been associated with the development of akathisia, characterized by subjectively unpleasant or painful restlessness, often accompanied by unsteadiness when sitting or standing and the need to move. This symptom usually occurs within a few weeks after administration. In patients experiencing these symptoms, increasing the dose of this drug may be harmful.
17) Serotonin syndrome: Not only are serotonin-norepinephrine reuptake inhibitors (SNRIs) and selective serotonin reuptake inhibitors (SSRIs) administered alone, but also other serotonergic drugs (triptan drugs, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's wort (St. The development of potentially life-threatening serotonin syndrome has been reported when coadministered with drugs that inhibit serotonin metabolism (including MAO inhibitors, both for the treatment of mental disorders, and other drugs such as linezolid and intravenous methylene blue).
Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, coma), autonomic instability (e.g., tachycardia, unstable blood pressure, dizziness, sweating, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, twitching, myoclonus, hyperreflexia, dyscoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome.
Co-administration of this agent and MAO inhibitors for the treatment of mental disorders is contraindicated. Additionally, treatment with MAO inhibitors such as linezolid or intravenous methylene blue should not be initiated in patients receiving MAO inhibitors. All postmarketing reports of methylene blue products for which route of administration information was provided include intravenous administration with a dose range of 1 mg/kg to 8 mg/kg. The reports do not include cases where methylene blue was administered by other routes of administration (such as tablets or local injection) or in low doses. Patients receiving this medication may need to start treatment with MAO inhibitors such as linezolid or intravenous methylene blue. This agent should be discontinued before starting MAO inhibitor treatment. (Refer to Dosage and Usage section and section 2. Do not administer to the following patients)
If coadministration of this agent with other serotonergic drugs, for example triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, and St. John's Wort, may be clinically beneficial, patients should be aware of the potential increased risk of serotonin syndrome, especially during treatment initiation and when increasing doses.
If the above-mentioned adverse reactions occur when co-administering this agent and serotonergic drugs, administration should be discontinued immediately and supportive symptomatic treatment should be initiated.
6. Interaction
The interaction study was conducted only on adults.
Like other drugs, there is a possibility of interaction through various mechanisms (pharmacokinetic and pharmacodynamic inhibition and enhancement).
1) MAO inhibitor: Refer to section 2. Do not administer to the following patients and section 5. General precautions in the directions and dosage section and section 5. Precautions for use.
2) Serotonin preparations: Refer to section 2. Do not administer to the following patients and section 5. General precautions in the directions and dosage section and section 5. Precautions for use.
3) Other antidepressants: When administered in combination with other antidepressants, the stable plasma concentration of other antidepressants increased more than twice.
4) Diazepam disappearance rate: The half-life of concomitantly administered diazepam may be prolonged in some patients.
5) Potential effects of co-administration with drugs with a high plasma protein binding rate: Since this drug binds strongly to plasma proteins, administration to patients receiving other drugs with a high protein binding rate (Coumadin, Digitoxin, etc.) may cause changes in plasma concentration and cause adverse reactions. Conversely, this also applies if this drug is replaced with another drug that binds strongly.
6) Central nervous system drugs: The risk of combined use of this drug with other central nervous system drugs has not been systematically evaluated, so caution is required when administering these drugs together.
7) Electroconvulsive therapy (ECT): There are no clinical studies on the benefits of combining electroconvulsive therapy (ECT) with this drug, and caution is advised as persistent seizures have rarely been reported in patients who received electroconvulsive therapy while receiving this drug.
8) Drugs metabolized by the cytochrome P450 2D6 isoenzyme: This drug has the potential to inhibit the cytochrome P450 2D6 isoenzyme, so in case of combined treatment with drugs significantly metabolized by the cytochrome P450 2D6 system and drugs with a relatively narrow therapeutic range, if the patient is taking this drug in combination or started taking it 5 weeks ago, start from the lowest therapeutic dose. Treatment should begin. If this drug is additionally administered to a patient taking such drugs, it is necessary to consider reducing the dose of the drug originally administered.
9) Drugs that inhibit hemostasis (e.g. NSAIDS, aspirin, warfarin): Serotonin release from platelets plays an important role in hemostasis. Epidemiological studies in case-control and cohort designs that demonstrated a correlation between the use of psychoactive drugs that inhibit serotonin reuptake and the occurrence of upper gastrointestinal bleeding indicated a possible risk of bleeding when coadministered with NSAIDs or aspirin. Modified anticoagulant effects, including increased bleeding, have been reported when SNRIs or SSRIs were coadministered with warfarin. Patients receiving warfarin should be carefully monitored when starting or discontinuing treatment with this drug.
10) Alcohol: In formal tests, this drug did not increase blood alcohol concentration or enhance the action of alcohol. However, consumption of alcohol is not recommended when taking this medicine.
11) QT interval prolongation: Pharmacodynamic and pharmacokinetic studies between fluoxetine and drugs that may prolong the QT interval have not been conducted. Since additive effects between fluoxetine and these drugs cannot be excluded, class IA and III antiarrhythmic drugs that may prolong the QT interval, antipsychotics (phenothiazine derivatives, pimozide, haloperidol), tricyclic antidepressants, antibacterial agents (sparfloxacin, moxifloxacin, erythromycin IV, pentamidine), antimalarials such as halofantrine, Caution should be used when coadministering this drug with antihistamines (astemizole, mizolastine).
7. Administration to pregnant and lactating women
1) During pregnancy, this drug should be used only when the potential benefits outweigh the potential risks to the fetus. All pregnancies, regardless of drug exposure, have a background risk of fetal defects, miscarriage, or other adverse outcomes. There have been no adequately controlled clinical trials in pregnant women. The results of many epidemiological studies assessing the risk of exposure to this drug in the first trimester of pregnancy have been inconsistent and have not provided conclusive evidence for an increased risk of congenital malformations. However, one meta-analysis suggested a potential risk of cardiovascular defects in infants of women exposed to this drug in the first trimester of pregnancy compared to infants of unexposed women. The mechanism of action is unknown. From epidemiological study data, the risk of cardiovascular defects in infants occurred at a rate of 2 per 100 pregnancies under fluoxetine treatment, compared to 1 per 100 pregnancies in the general population. Epidemiological studies have shown that the administration of SSRIs during pregnancy, especially in the third trimester, may increase the risk of persistent pulmonary hypertension of the newborn (PPHN). The observed risk was approximately 5 cases per 1,000 pregnant women. Typically, PPHN occurs at a rate of 1 to 2 cases per 1,000 pregnant women.
In particular, caution should be exercised when using this drug in late pregnancy or just before the start of labor, as the following cases have been reported in newborns: irritability, tremors, hypotonia, persistent crying, and difficulty suckling or sleeping. These symptoms may be serotonergic or indicative of withdrawal symptoms. The time of onset and duration of symptoms may be related to the long half-life of fluoxetine (4 to 6 days) and its active ingredient norfluoxetine (4 to 16 days).
Observational study data provide evidence for an increased risk (less than 2-fold) of postpartum hemorrhage following exposure to SSRIs or SNRIs in the month before delivery. Although there are no studies examining the relationship between treatment with this drug and postpartum hemorrhage, a risk cannot be ruled out considering the mechanism of action of this drug.
2) Lactation: Fluoxetine and its active ingredient, norfluoxetine, are known to be secreted into human breast milk. Adverse events have been reported in breastfed infants. If treatment with this drug is deemed necessary, discontinuation of breast-feeding should be considered. However, if breastfeeding continues, the minimum effective dose of this drug should be prescribed.
3) Animal tests have shown that this drug may affect sperm quality. Case reports involving some SSRIs have shown that their effects on human sperm quality are reversible. Effects on human fertility have not yet been observed.
8. Administration to children and adolescents
Because the safety and efficacy in children and adolescents have not been established, it is recommended not to administer this drug (see Warnings and Adverse Reactions section).
9. Administration to elderly people
Although its use in older people has not been fully evaluated, no age-related adverse reactions were found. However, age-related adverse reactions cannot be ruled out in elderly patients with concurrent diseases or taking other drugs concomitantly.
10. Treatment in case of overdose
1) Overdosage of this drug alone generally resulted in a mild course. Symptoms of overdose have included nausea, vomiting, seizures, asymptomatic arrhythmias (including nodal rhythms and ventricular arrhythmias) or cardiovascular disorders ranging from electrocardiographic changes indicative of QTc prolongation to cardiac arrest (including very rare cases of torsade de pointes), pulmonary dysfunction, and signs of CNS changes ranging from agitation to coma. Deaths due to overdose of this drug alone are very rare. Monitoring of the heart and vital signs along with routine symptomatic and supportive care is recommended. No specific antidote is known.
Forced diuresis, renal dialysis, hemoperfusion, and exchange transfusion may not be beneficial. Activated charcoal, which can be used with sorbitol, may be equally or more effective than vomiting or gastric lavage. When managing overdose, the involvement of other drugs must be taken into consideration. If the patient is currently taking this medication or has recently taken this medication and has taken an overdose of a tricyclic antidepressant, extended close medical observation may be necessary.
11. Pharmaceutical equivalence test information
A. The test drug Fluoxetine Hydrochloride Capsule 20 mg (HLB Pharmaceutical Co., Ltd.) and the control drug Furozac Capsule 20 mg (Fluoxetine Hydrochloride) [Lilli Korea Ltd.] were administered orally once on an empty stomach to healthy adults in a 2x2 crossover test. As a result, blood fluoxetine was measured in 30 people. The comparative evaluation values (AUCt, Cmax) were log-transformed. When subjected to statistical processing, the 90% confidence interval of the mean difference was within log0.8 to log1.25, proving biological equivalence.
- Table: Refer to manual -
B. In accordance with Article 7, Paragraph 2 of the Pharmaceutical Equivalence Test Standards, the test drug Fluoxetine Hydrochloride Capsule 10 mg [HLB Pharmaceutical Co., Ltd.] submitted comparative dissolution test data with the reference drug Fluoxetine Hydrochloride Capsule 20 mg [HLB Pharmaceutical Co., Ltd.], and the dissolution pattern was equivalent to that of the reference drug. Accordingly, bioequivalence was proven with the relevant data.
12. Others
1) Laboratory tests: There are no particularly recommended tests.
2) Carcinogenicity, mutagenicity, impairment of fertility: No carcinogenicity was found when administered to rats and mice for 2 years at doses of 10mg/kg/day and 12mg/kg/day, which are 1.2 and 0.7 times (per mg/m2) of the recommended maximum human dose (80mg). Fluoxetine and norfluoxetine did not show genotoxicity in bacterial mutation tests, DNA repair tests in cultured rat hepatocytes, lymphoma tests in mice, and sister chromatid exchange tests using Chinese hamster bone marrow cells. In two studies in which fluoxetine was administered to adult rats at doses of 7.5 mg/kg/day and 12.5 mg/kg/day (approximately 0.9 and 1.5 times the maximum recommended human dose per mg/m2), fluoxetine did not affect fertility. However, when administered to juvenile rats, adverse reactions occurred in terms of fertility.
3) Toxicity in animal experiments: Phospholipids increased in some tissues of mice, rats, and dogs that received this drug long-term, and this was found to be reversible after stopping treatment. In animals, phospholipid accumulation has been observed with the use of many positive cationic drugs, including fenfluramine, imipramine, and ranitidine, but the significance of this effect in humans is unknown.
4) Limited to Western capsules
① This drug is a controlled-release capsule filled with enteric-coated granules, and the drug does not dissolve until the pH of the gastrointestinal tract reaches 5.5 or higher. Due to this enteric coating, the absorption of fluoxetine is delayed by 1 to 2 hours compared to the immediate-release formulation.
② When this drug is administered once a week, the difference between the peak and trough concentrations of fluoxetine and norfluoxetine in the blood is greater than when administered once a day. (Fluoxetine: 24% (once a day), 164% (once a week), Norfluoxetine: 17% (once a day), 43% (once a week)) Plasma concentrations do not necessarily correspond to clinical responses. When this drug is administered once a week, the peak concentration is within the range of the average concentration when 20 mg is administered once a day. The average trough concentration is 76% lower for fluoxetine and 47% lower for norfluoxetine than when administered at 20 mg once daily. The average steady-state concentration was proportional to the total dose administered for both once-daily and once-weekly administration. When administered once a week compared to once a day, the average steady-state concentration is lowered by about 50%. When changing to once-a-week administration the next day after administering 20mg once a day, the highest blood concentration when administering 90mg once a week reached almost 1.7 times the highest blood concentration when administering 20mg once a day. On the other hand, when the changes were made at intervals of one week, the highest concentration in the blood was similar. The average fluoxetine steady-state concentration also increased when the treatment was changed to once a week the next day. From a pharmacodynamic point of view, it is advisable to leave an interval of one week between the last dose of 20 mg once daily and the first dose of 90 mg once a week.
13. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 capsules/bottle
7. Period of use
24 months from date of manufacture
- Active ingredient: Fluoxetine hydrochloride (USP) 22.4mg (20.0mg as fluoxetine)
- Additives (tar coloring): Blue No. 1
- Other additives: magnesium stearate, citric acid hydrate, corn starch, sodium starch glycolate, capsule, D-mannitol
2. Effectiveness
1. Depression
The drug's effectiveness was seen within 5 to 6 weeks in the treatment of outpatients with depression diagnosed as very similar to DSM-III category depression. Depression is a persistent state of depression or malaise (almost daily for at least two weeks) that is usually significant enough to interfere with daily functioning and must include at least four of the following eight symptoms: changes in appetite, changes in sleep, psychomotor irritability or fatigue, lack of interest in daily life or decreased sexual desire, increased fatigue, feelings of guilt or worthlessness, slowed thinking or difficulty concentrating, and suicide attempts or thoughts of suicide.
The antidepressant effect of this drug on hospitalized depressed patients has not been adequately studied so far, and its effectiveness for long-term administration over 5 to 6 weeks has not been systematically evaluated through controlled trials. Therefore, its usefulness for individual patients is regularly reevaluated when administered long-term.
2. Bulimia nervosa
This drug showed a significant reduction in gluttony and binge-seeking behavior compared to the placebo group. The effectiveness of this drug for long-term administration over 16 weeks has not been systematically evaluated through controlled trials, so its usefulness for individual patients must be regularly reevaluated during long-term administration.
3. Obsessive-compulsive disorder
This drug significantly reduced symptoms of obsessive-compulsive disorder in a double-blind, placebo-controlled clinical trial. To suddenly experience obsessions or compulsions that become quite distressing, time-consuming, or significantly disrupt a person's social or work life. The effectiveness of this drug for long-term administration over 13 weeks has not been systematically evaluated through controlled trials, so its usefulness for individual patients must be regularly reevaluated during long-term administration.
4. Premenstrual dysphoric disorder
Premenstrual dysphoria symptoms, such as depression, anxiety, and emotional instability, appear periodically (the last week of the luteal phase in the menstrual cycle) and disappear within a few days when menstruation begins. These symptoms interfere with social roles and job performance and are accompanied by physical symptoms such as breast pain, headache, joint or muscle pain, abdominal bloating, and weight gain. General premenstrual tension and periodic mental disorders due to antidepressant treatment are excluded from premenstrual dysphoria symptoms. The effectiveness of this drug when used for long periods of more than 6 months has not yet been systematically evaluated. Therefore, doctors who plan to use this drug for a long period of time should regularly re-evaluate the effectiveness of long-term use for each patient.
3. Dosage and dosage
- Adult
1. Depression
1) Initial treatment: The initial dose is fluoxetine hydrochloride, 20 mg orally once a day in the morning.
In controlled clinical trials, doses of 20 to 80 mg per day were administered. If no improvement is observed, an increase in dose may be considered after a few weeks. Doses exceeding 20 mg per day should be administered twice a day (morning and noon) and the maximum dose of 80 mg per day should not be exceeded. The onset of sufficient antidepressant effects may be delayed until 4 weeks or more after treatment.
2) Maintenance/continuing/extended treatment: Although there is no clear data on how long a patient should be treated with this drug, it is recognized among psychopharmacologists that acute signs of depression require drug treatment for several months or more. It is not known whether the amount of antidepressant medication needed to relieve symptoms is the same as the amount needed to maintain or sustain stability.
2. Bulimia nervosa
This drug is administered at 60 mg per day. The daily dosage does not exceed 80 mg.
Measure electrolyte concentrations before starting treatment.
3. Obsessive-compulsive disorder
This drug is administered in doses of 20 to 60 mg per day. The daily dosage does not exceed 80 mg.
4. Premenstrual dysphoric disorder
This drug is administered at 20 mg per day.
After 6 months of treatment, re-evaluate whether continued treatment is necessary.
- Patients with kidney and/or liver damage, patients receiving multiple medications, the elderly, and patients with concomitant diseases: Administer a lower dose or reduce the frequency of administration. Increase or decrease appropriately depending on age and symptoms.
- Related to switching to MAO inhibitors to treat mental illness
When discontinuing treatment with an MAO inhibitor for the treatment of mental illness and starting treatment with the same drug, there must be an interval of at least 14 days. Conversely, before starting treatment with an MAO inhibitor for the treatment of mental illness, at least 5 weeks must elapse after discontinuation of the drug.
- Other MAO inhibitors such as linezolid or methylene blue
Patients receiving linezolid or intravenous methylene blue products should not begin treatment with these products due to the increased risk of serotonin syndrome. Administration should be considered in patients requiring hospitalization, other interventional procedures, or treatment of more urgent psychiatric conditions.
There may be a need to urgently administer linezolid or intravenous methylene blue to patients who are already receiving this medication. If there is no alternative drug to linezolid or intravenous methylene blue and the benefit of treatment with linezolid or intravenous methylene blue is judged to outweigh the risk of serotonin syndrome in a specific patient, the medication should be discontinued immediately and linezolid or intravenous methylene blue should be administered immediately. The preparation can be administered. Patients should be monitored for symptoms of serotonin syndrome for 5 weeks after receiving linezolid or intravenous methylene blue products or 24 hours after the last dose, whichever comes first. Treatment with linezolid or intravenous methylene blue can be restarted 24 hours after the last dose.
The risk of administering methylene blue preparation non-intravenously (oral tablet or local injection) or injecting less than 1 mg/kg intravenously is not clear. Nevertheless, clinicians should be aware of the potential for emergent symptoms of serotonin syndrome with this use.
4. Precautions for use
1. Warning
- Suicidality and antidepressants
In short-term studies of children, adolescents, and young adults (ages 18 to 24) with major depression or other psychiatric disorders, it has been reported that antidepressants increase the risk of suicidal thoughts and behaviors (suicidality) compared to placebo. Physicians considering administering this drug or other antidepressants to children, adolescents, or young adults should always carefully consider whether the clinical need outweighs the risks. In short-term studies, antidepressants did not increase the risk of suicidality compared with placebo in adults over 25 years of age, and this risk was reduced with antidepressants compared to placebo in adults over 65 years of age. Depression and other psychiatric disorders themselves are associated with an increased risk of suicide. Patients of any age starting treatment with antidepressants should be appropriately monitored and carefully observed for worsening disease, suicidal tendencies, or changes in other abnormal behaviors such as hostility, aggression, or anger. The patient's family or guardian is also instructed to observe the patient carefully and contact the doctor if necessary. This drug is not approved for use in children and adolescents.
2. Do not administer to the following patients
1) Patients with a history of hypersensitivity to this drug or its additives
2) Patients with severe renal impairment (glomerular filtration rate <10 mL/min)
3) Patients taking MAO inhibitors
: Co-administration of this drug and MAO inhibitors for the treatment of mental illness or administration of MAO inhibitors within 5 weeks after discontinuation of this drug is contraindicated because it increases the risk of serotonin syndrome. It is also contraindicated to administer this drug within 14 days of discontinuing treatment with MAO inhibitors for the treatment of mental disorders. (Refer to the Usage/Dosage section and 5. General Precautions section)
Starting treatment with this drug in patients receiving MAO inhibitors such as linezolid or intravenous methylene blue is also contraindicated due to the increased risk of serotonin syndrome (see Dosage and Administration section and 5. General Precautions).
3. Administer with caution to the following patients:
1) Seizures: Antidepressants have a potential risk of seizures. Therefore, like other antidepressants, this drug should be used with caution in patients with a history of seizures, and treatment should be discontinued if seizures appear or the number of seizures increases. This drug should be avoided in patients with unstable seizure disorders/epilepsy and should be carefully monitored in patients with controlled epilepsy.
2) Patients with a predisposition to suicide: Depression is associated with an increased risk of suicidal impulses, self-harm, and suicide (cases associated with suicide). This risk persists until depression is significantly reduced. Symptoms may not improve during the first few weeks or longer of treatment, so patients should be closely observed until improvement occurs. General clinical experience shows that the risk of suicide may increase in the early stages of recovery.
Other psychiatric conditions for which this drug is prescribed may also be associated with an increased risk of suicide-related events. These conditions may accompany major depressive disorder. The same precautions as when treating patients with major depressive disorder should be observed when treating patients with other mental disorders. Patients who have had significant suicidal thoughts and a history of suicide before starting treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and such patients should be carefully observed during treatment.
A meta-analysis of placebo-controlled clinical trials of antidepressants in adult patients with mental illness found an increased risk of suicidal behavior with antidepressant use compared with placebo in patients younger than 25 years. Close supervision of patients, especially those at high risk, should be performed while administering drug therapy, especially at the time of initial treatment and after dose changes.
Patients and caregivers should be informed of the need to monitor for clinical worsening, suicidal behavior or impulses, and unusual changes in behavior. They should seek medical attention immediately if these symptoms occur.
3) Mania: Antidepressants should be used with caution in patients with a history of mania or hypomania. As with other antidepressants, this drug should be discontinued in patients who enter a manic period.
4) Cardiovascular effects: As a result of post-marketing surveillance, ventricular arrhythmias including QT interval prolongation and torsade de pointes were reported (see Adverse Reactions, Interactions, and Treatment in Case of Overdose). Fluoxetine should be used with caution in patients with congenital long QT syndrome, a family history of QT interval prolongation, or clinical conditions predisposing to arrhythmias (e.g., hypokalemia, hypomagnesemia, bradycardia, and acute myocardial infarction or uncompensated heart failure), or in patients with increased exposure to this drug (e.g., patients with hepatic impairment). In patients with stable heart disease, an electrocardiogram should be considered before starting treatment with this drug. If signs of cardiac arrhythmia appear during treatment with this drug, treatment should be discontinued and an electrocardiogram should be measured.
5) Patients with hepatic/renal impairment: This drug is extensively metabolized in the liver and excreted through the kidneys. Lower doses (e.g., taken every other day) are recommended for patients with significant hepatic dysfunction. When patients with severe renal impairment (GFR <10 ml/min) requiring dialysis were treated with 20 mg/day of this drug for two months, there was no difference in plasma levels of fluoxetine or norfluoxetine compared to controls with normal renal function.
6) Patients with diabetes: In diabetic patients, blood sugar control may change with the administration of SSRIs. Hypoglycemia occurred during treatment with this drug, and hyperglycemia occurred after discontinuation. Dosage adjustments of insulin and/or oral hypoglycemic agents may be necessary to control blood sugar.
7) Pupil dilation: Pupil dilation has been reported associated with this drug. Therefore, it should be used with caution in patients with increased intraocular pressure or at risk of acute narrow-angle glaucoma.
4. Adverse reactions
1) The most commonly reported adverse reactions when administering fluoxetine are headache, nausea, insomnia, fatigue, and diarrhea. The following table shows adverse reactions observed in clinical trials (9,297 people) and spontaneous reports.
Frequency assessment: very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1,000, <1/100), rare (≥1/10,000, <1/1,000), very rare (<1/10,000), frequency unknown.
(Table. Refer to attached document)
1 Including loss of appetite
2 Includes early morning waking or early and moderate insomnia
3 nightmares included
4 Including loss of sexual desire
Includes 5-sex frigidity
6 Includes hypersomnia and sedation
7 Includes hot flashes
8 Includes erythema, exfoliative rash, heat rash, rash, erythematous rash, follicular rash, generalized rash, macular rash, maculo-papular rash, measlesoid rash, papular rash, itchy rash, bullous rash, and umbilical rash.
9 Including frequent urination
10 Includes ejaculation failure, ejaculation disorder, premature ejaculation, delayed ejaculation, and retrograde ejaculation
11 Includes cervical bleeding, uterine dysfunction, uterine bleeding, genital bleeding, functional uterine bleeding, menorrhagia, frequent menstruation, postmenopausal bleeding, vaginal bleeding
12 Including asthenia
13 May progress to Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (Lyell syndrome)
14 This symptom may be caused by an underlying disease
15 The most frequently occurring include gum bleeding, hematemesis, hematochezia, rectal bleeding, bloody diarrhea, melena, and gastric ulcer bleeding.
16 In post-marketing experience, cases of persistent sexual dysfunction symptoms when discontinuing treatment with this drug have been reported in very rare cases.
2) Suicidal tendency: Increased suicidal tendency in children, adolescents, and young adults (18-24 years old): Cases of suicidal ideation and suicidal behavior have been reported during fluoxetine treatment or in the early stages of discontinuation of fluoxetine treatment (see Warning section 1).
3) Fracture: An epidemiological study conducted mainly on patients over 50 years of age showed that the risk of fracture increased in patients taking SSRIs and TCAs. The mechanism of this risk has not been identified.
4) Withdrawal symptoms that appear when discontinuing fluoxetine administration: Withdrawal symptoms commonly appear when discontinuing fluoxetine administration. The most commonly reported reactions are dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and violent dreams), asthenia, agitation or anxiety, nausea and/or vomiting, tremors, and headache. Typically, these events were mild to moderate and self-limiting, but in some patients they were severe and/or persistent. Therefore, if this drug is no longer needed, the drug should be gradually discontinued by reducing the dose.
5) Rash and allergic reactions: Rash, anaphylactoid reactions and progressive systemic reactions, sometimes severe (involving the skin, kidneys, liver or lungs) have been reported. If rash or other allergic symptoms for which no other etiology can be identified appear, administration of this drug should be discontinued.
6) Weight loss: Weight loss may occur in patients taking this drug, but is generally proportional to baseline body weight.
7) Children and adolescents: In pediatric clinical trials, suicide-related behaviors (suicide attempts and suicidal impulses) and hostility were more commonly observed in children and adolescents administered antidepressants compared to the placebo group. In pediatric clinical trials, manic reactions including mania and hypomania were reported (fluoxetine group: 2.6%, placebo group: 0%), and most of the cases were discontinued. These patients had no previous episodes of hypomania or mania.
After 19 weeks of treatment, pediatric patients who received fluoxetine in clinical trials showed 1.1 cm (1.0 cm vs 2.1 cm, p = 0.004) lower height and 1.1 kg (1.2 kg vs 2.3 kg, p = 0.008) lower body weight compared to the placebo group, and cases of growth retardation were also reported in clinical use. Administration of fluoxetine was associated with a decrease in alkaline phosphatase levels.
It has not been established whether the height and weight loss observed in the 19-week clinical trial affects the ability to reach normal adult height. In addition, adverse reactions indicating potential delayed sexual maturation or sexual dysfunction have been reported from clinical use in children, and since the possibility of delayed puberty cannot be ruled out, growth and pubertal development (height, weight, tanner stage) should be observed during and after administration of this drug. If any developmental delays are observed, consultation with a pediatrician should be considered. The safety of fluoxetine for long-term administration over 19 weeks has not been systematically evaluated.
8) Hyponatremia: Hyponatremia (serum sodium concentration below 110 mmol/l in some cases) has been reported. Hyponatremia appeared to resolve when treatment with this drug was discontinued. These cases are complex with varying possible etiologies, but some may be attributed to syndrome of abnormal antidiuretic hormone secretion (SIADH). Most of these cases occurred in elderly patients, patients taking diuretics, or patients with volume deficiency.
9) Platelet function: Changes in platelet function and/or abnormal results through laboratory tests have been rarely reported in patients receiving this drug. There have been reports of abnormal bleeding in several patients receiving this drug, but it is unclear whether this effect was caused by the drug.
10) Post-marketing surveillance
Following approval of this drug, the following adverse reactions were identified: Because these reactions were voluntarily reported from a patient population of unspecified size, it is difficult to determine whether the frequency is reliable or the causal relationship with drug exposure. Adverse reactions temporally related to this drug administered after marketing, and voluntarily reported adverse reactions that may not be causally related to the drug, are as follows:
Aplastic anemia, atrial fibrillation1, cataract, cerebrovascular accident1, cholestatic jaundice, dyskinesia (for example, in a 77-year-old female patient who received this drug for 5 weeks, chewing syndrome of the cheek and tongue due to involuntary tongue protrusion completely disappeared within a few months after stopping the drug), eosinophilic pneumonia, epithelial necrosis, erythema multiforme, erythema nodosum, exfoliative dermatitis, Gynecomastia, cardiac arrest1, liver failure/necrosis, hyperprolactinemia, hypoglycemia, immune-related hemolytic anemia, renal failure, movement disorders and exacerbation of existing movement disorders in patients with risk factors including drugs associated with these reactions, optic neuritis, pancreatitis1, pancytopenia, pulmonary embolism, pulmonary hypertension1, QT prolongation, Stevenson-Johnson syndrome, thrombocytopenia1, thrombocytopenic purpura, Ventricular tachycardia (including torsades de pointes type arrhythmia), vaginal bleeding, aggressive behavior1.
1 These terms represent serious adverse events but do not meet the definition of adverse events. These reactions are included here because of their severity.
5. General precautions
1) Long half-life of this drug and its metabolites: Due to the long half-life of this drug (2-3 days) and its main metabolite (7-9 days), changes in dosage are not fully reflected for several weeks, which also affects the determination of the final dose and termination of treatment. (Refer to the Dosage and Administration section)
2) Interference with cognition and motor performance: Like other psychotropic drugs, this drug may impair judgment, thinking, or motor function, so patients should be cautious when operating dangerous machinery, such as driving a car, until they are reasonably sure that performance will not be affected.
3) Use of concomitant drugs or alcohol: Patients should seek advice from their doctor if they are taking or plan to take general or specialty drugs, including alcohol or herbal medicines. You should also seek medical advice if you plan to stop taking any medications while taking Furozac.
4) Physical and mental dependence: Abuse potential, tolerance, and physical dependence have not been systematically studied in animals and humans. Although clinical trials have not revealed withdrawal syndromes or drug-seeking behaviors, these observations are not systematic, and based on this limited experience, it is not possible to predict the extent to which central nervous system-active drugs will be subject to misuse, diversion, or abuse once they become available. Therefore, it is necessary to determine whether the patient has experienced drug abuse in the past, and carefully observe and track whether there are signs of drug abuse or misuse (development of tolerance, increased dosage, drug-seeking behavior).
5) Unlike the treatment of depression, the treatment effect for premenstrual dysphoric disorder appears very quickly, and symptoms generally improve in the first cycle of treatment. Clinical trials have shown that symptoms tend to reappear quickly, usually within 1-2 cycles, after stopping treatment. Before starting treatment for premenstrual dysphoric disorder, patients should be fully informed of the benefits and risks of taking this drug.
6) Patients (adults, children) with major depression, even if taking antidepressants, may experience worsening of depressive symptoms, suicidal thoughts and behaviors (suicidal tendencies), and abnormal behavior changes until the disease shows significant improvement.
7) Suicide is a known risk factor for depression and certain other psychiatric disorders, and these disorders are themselves the strongest predictors of suicide. However, there has been long-standing concern that antidepressants may lead to worsening of depressive symptoms and the development of suicidality in some patients during the early stages of treatment. A pooled analysis of placebo-controlled, short-term clinical trials of antidepressants (SSRIs and others) indicates that these drugs increase the risk of suicidal thoughts and behaviors (suicidality) in children, adolescents, and young adults (18-24 years) with major depression and other psychiatric disorders. In short-term studies, antidepressants did not increase the risk of suicidality compared with placebo in adults over 25 years of age. In adults over 65 years of age, this risk was reduced with antidepressants compared to placebo.
8) A pooled analysis of placebo-controlled clinical trials in children and adolescents with major depression, obsessive-compulsive disorder, or other psychiatric disorders included a total of 24 short-term clinical trials of 9 antidepressants in more than 4,400 patients. The pooled analysis of placebo-controlled clinical trials in adults with major depression and other psychiatric disorders included a total of 295 short-term (median duration: 2 months) clinical trials of 11 antidepressants in more than 77,000 patients. Although there were significant differences in the risk of suicidality among drugs, there was a trend toward increased suicidality in young adults for most all drugs studied. There were differences in the absolute risk of suicidality among different indications, with the highest incidence occurring in major depression. However, the difference in risk (antidepressants vs. placebo) was relatively stable within age groups and between indications. These risk differences (differences between antidepressants and placebo in the number of suicidal tendencies per 1,000 treated patients) are shown in Table 1 below.
(Refer to Table 1 and attached document)
9) Suicide did not occur in any pediatric clinical trials. Suicides occurred in clinical trials in adults, but the numbers were not sufficient to draw any conclusions about the drug's effect on suicide. It is not known whether the risk of suicidality extends to long-term (i.e., more than several months) use of the drug. However, there is ample evidence from ongoing placebo-controlled clinical trials in adults with depression that the use of antidepressants may delay the recurrence of depression.
10) It is unknown whether there is an increase in suicidal tendencies in adults or in patients receiving long-term treatment for more than several months, but patients using antidepressants should be carefully monitored for changes in suicidal tendencies, self-harm, hostility, and any abnormal behavior during the first few months of treatment or when changing the dose (increase or decrease).
11) Patients of all ages using antidepressants may experience anxiety, agitation, panic disorder, insomnia, excitement, hostility, aggression, impulsivity, akathisia, hypomania, and mania. Although the correlation with these symptoms is unclear, caution should be exercised as they may be precursor symptoms of suicidal tendencies. In addition, instruct family members and guardians to monitor these symptoms or suicidal tendencies daily and notify the doctor immediately when symptoms appear.
12) If depressive symptoms continue to worsen, suicidal tendencies appear, or symptoms that may be prodromal symptoms of suicidal tendencies (severe or sudden symptoms, symptoms not originally present in the patient) appear, discontinuation of this drug should be considered.
13) Although not proven in controlled clinical trials, the use of antidepressants during a depressive episode in patients with bipolar disorder may promote manic or manic episodes. Therefore, before administering antidepressants, a detailed psychiatric history, including family history of suicide, bipolar disorder, or depression, should be checked to screen for the possibility of bipolar disorder.
14) Withdrawal symptoms observed when SSRI treatment is discontinued: Withdrawal symptoms are particularly common when treatment is stopped suddenly. In clinical trials, adverse reactions observed upon discontinuation of treatment occurred in approximately 60% of patients in both the acetabine and placebo groups. Of these adverse events, 17% in the ZERO drug group and 12% in the placebo group were serious in nature. The risk of withdrawal symptoms may vary depending on several factors, including treatment duration, dose, and rate of dose reduction. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), asthenia, nervousness or anxiety, nausea and/or vomiting, tremors and headaches are the most commonly reported reactions. Typically, these symptoms are mild to moderate in severity, but may be severe in some patients. These symptoms usually appear within the first few days after stopping treatment. Although in some patients these symptoms may persist (for longer than 2-3 months), symptoms generally heal on their own and usually disappear within 2 weeks. Therefore, depending on the patient's needs, it is recommended to gradually reduce the dose over a period of at least 1-2 weeks when discontinuing treatment. When discontinuing the administration of this drug, patients should be monitored to see if these symptoms appear, and patients or guardians should not unilaterally stop taking this drug without consulting the prescribing doctor. If intolerable symptoms occur due to reduction or discontinuation of treatment, re-administration of the previously prescribed dose may be considered. After that, you can continue to reduce weight more gradually. The risk of symptoms due to discontinuation of this drug can be minimized by gradually reducing plasma fluoxetine and norfluoxetine concentrations until the end of treatment.
15) Bleeding: Abnormal skin bleeding, such as ecchymosis and purpura, has been reported with SSRI drugs. Antidepressants with serotonergic effects may increase the risk of postpartum hemorrhage. Ecchymosis has been uncommonly reported during treatment with this drug. Other bleeding events (vaginal bleeding, gastrointestinal bleeding, and other skin or mucous membrane bleeding) have been rarely reported. Caution is advised in patients with a history of bleeding disorders, as well as those taking SSRIs, anticoagulants, drugs known to affect platelet function (atypical antipsychotics such as clozapine, phenothiazines, most tricyclic antidepressants (TCAs), aspirin, NSAIDS), or other drugs that may increase the risk of bleeding.
16) Akathisia/psychomotor restlessness: Fluoxetine use has been associated with the development of akathisia, characterized by subjectively unpleasant or painful restlessness, often accompanied by unsteadiness when sitting or standing and the need to move. This symptom usually occurs within a few weeks after administration. In patients experiencing these symptoms, increasing the dose of this drug may be harmful.
17) Serotonin syndrome: Not only are serotonin-norepinephrine reuptake inhibitors (SNRIs) and selective serotonin reuptake inhibitors (SSRIs) administered alone, but also other serotonergic drugs (triptan drugs, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John's wort (St. The development of potentially life-threatening serotonin syndrome has been reported when coadministered with drugs that inhibit serotonin metabolism (including MAO inhibitors, both for the treatment of mental disorders, and other drugs such as linezolid and intravenous methylene blue).
Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, coma), autonomic instability (e.g., tachycardia, unstable blood pressure, dizziness, sweating, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, twitching, myoclonus, hyperreflexia, dyscoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome.
Co-administration of this agent and MAO inhibitors for the treatment of mental disorders is contraindicated. Additionally, treatment with MAO inhibitors such as linezolid or intravenous methylene blue should not be initiated in patients receiving MAO inhibitors. All postmarketing reports of methylene blue products for which route of administration information was provided include intravenous administration with a dose range of 1 mg/kg to 8 mg/kg. The reports do not include cases where methylene blue was administered by other routes of administration (such as tablets or local injection) or in low doses. Patients receiving this medication may need to start treatment with MAO inhibitors such as linezolid or intravenous methylene blue. This agent should be discontinued before starting MAO inhibitor treatment. (Refer to Dosage and Usage section and section 2. Do not administer to the following patients)
If coadministration of this agent with other serotonergic drugs, for example triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone, tryptophan, and St. John's Wort, may be clinically beneficial, patients should be aware of the potential increased risk of serotonin syndrome, especially during treatment initiation and when increasing doses.
If the above-mentioned adverse reactions occur when co-administering this agent and serotonergic drugs, administration should be discontinued immediately and supportive symptomatic treatment should be initiated.
6. Interaction
The interaction study was conducted only on adults.
Like other drugs, there is a possibility of interaction through various mechanisms (pharmacokinetic and pharmacodynamic inhibition and enhancement).
1) MAO inhibitor: Refer to section 2. Do not administer to the following patients and section 5. General precautions in the directions and dosage section and section 5. Precautions for use.
2) Serotonin preparations: Refer to section 2. Do not administer to the following patients and section 5. General precautions in the directions and dosage section and section 5. Precautions for use.
3) Other antidepressants: When administered in combination with other antidepressants, the stable plasma concentration of other antidepressants increased more than twice.
4) Diazepam disappearance rate: The half-life of concomitantly administered diazepam may be prolonged in some patients.
5) Potential effects of co-administration with drugs with a high plasma protein binding rate: Since this drug binds strongly to plasma proteins, administration to patients receiving other drugs with a high protein binding rate (Coumadin, Digitoxin, etc.) may cause changes in plasma concentration and cause adverse reactions. Conversely, this also applies if this drug is replaced with another drug that binds strongly.
6) Central nervous system drugs: The risk of combined use of this drug with other central nervous system drugs has not been systematically evaluated, so caution is required when administering these drugs together.
7) Electroconvulsive therapy (ECT): There are no clinical studies on the benefits of combining electroconvulsive therapy (ECT) with this drug, and caution is advised as persistent seizures have rarely been reported in patients who received electroconvulsive therapy while receiving this drug.
8) Drugs metabolized by the cytochrome P450 2D6 isoenzyme: This drug has the potential to inhibit the cytochrome P450 2D6 isoenzyme, so in case of combined treatment with drugs significantly metabolized by the cytochrome P450 2D6 system and drugs with a relatively narrow therapeutic range, if the patient is taking this drug in combination or started taking it 5 weeks ago, start from the lowest therapeutic dose. Treatment should begin. If this drug is additionally administered to a patient taking such drugs, it is necessary to consider reducing the dose of the drug originally administered.
9) Drugs that inhibit hemostasis (e.g. NSAIDS, aspirin, warfarin): Serotonin release from platelets plays an important role in hemostasis. Epidemiological studies in case-control and cohort designs that demonstrated a correlation between the use of psychoactive drugs that inhibit serotonin reuptake and the occurrence of upper gastrointestinal bleeding indicated a possible risk of bleeding when coadministered with NSAIDs or aspirin. Modified anticoagulant effects, including increased bleeding, have been reported when SNRIs or SSRIs were coadministered with warfarin. Patients receiving warfarin should be carefully monitored when starting or discontinuing treatment with this drug.
10) Alcohol: In formal tests, this drug did not increase blood alcohol concentration or enhance the action of alcohol. However, consumption of alcohol is not recommended when taking this medicine.
11) QT interval prolongation: Pharmacodynamic and pharmacokinetic studies between fluoxetine and drugs that may prolong the QT interval have not been conducted. Since additive effects between fluoxetine and these drugs cannot be excluded, class IA and III antiarrhythmic drugs that may prolong the QT interval, antipsychotics (phenothiazine derivatives, pimozide, haloperidol), tricyclic antidepressants, antibacterial agents (sparfloxacin, moxifloxacin, erythromycin IV, pentamidine), antimalarials such as halofantrine, Caution should be used when coadministering this drug with antihistamines (astemizole, mizolastine).
7. Administration to pregnant and lactating women
1) During pregnancy, this drug should be used only when the potential benefits outweigh the potential risks to the fetus. All pregnancies, regardless of drug exposure, have a background risk of fetal defects, miscarriage, or other adverse outcomes. There have been no adequately controlled clinical trials in pregnant women. The results of many epidemiological studies assessing the risk of exposure to this drug in the first trimester of pregnancy have been inconsistent and have not provided conclusive evidence for an increased risk of congenital malformations. However, one meta-analysis suggested a potential risk of cardiovascular defects in infants of women exposed to this drug in the first trimester of pregnancy compared to infants of unexposed women. The mechanism of action is unknown. From epidemiological study data, the risk of cardiovascular defects in infants occurred at a rate of 2 per 100 pregnancies under fluoxetine treatment, compared to 1 per 100 pregnancies in the general population. Epidemiological studies have shown that the administration of SSRIs during pregnancy, especially in the third trimester, may increase the risk of persistent pulmonary hypertension of the newborn (PPHN). The observed risk was approximately 5 cases per 1,000 pregnant women. Typically, PPHN occurs at a rate of 1 to 2 cases per 1,000 pregnant women.
In particular, caution should be exercised when using this drug in late pregnancy or just before the start of labor, as the following cases have been reported in newborns: irritability, tremors, hypotonia, persistent crying, and difficulty suckling or sleeping. These symptoms may be serotonergic or indicative of withdrawal symptoms. The time of onset and duration of symptoms may be related to the long half-life of fluoxetine (4 to 6 days) and its active ingredient norfluoxetine (4 to 16 days).
Observational study data provide evidence for an increased risk (less than 2-fold) of postpartum hemorrhage following exposure to SSRIs or SNRIs in the month before delivery. Although there are no studies examining the relationship between treatment with this drug and postpartum hemorrhage, a risk cannot be ruled out considering the mechanism of action of this drug.
2) Lactation: Fluoxetine and its active ingredient, norfluoxetine, are known to be secreted into human breast milk. Adverse events have been reported in breastfed infants. If treatment with this drug is deemed necessary, discontinuation of breast-feeding should be considered. However, if breastfeeding continues, the minimum effective dose of this drug should be prescribed.
3) Animal tests have shown that this drug may affect sperm quality. Case reports involving some SSRIs have shown that their effects on human sperm quality are reversible. Effects on human fertility have not yet been observed.
8. Administration to children and adolescents
Because the safety and efficacy in children and adolescents have not been established, it is recommended not to administer this drug (see Warnings and Adverse Reactions section).
9. Administration to elderly people
Although its use in older people has not been fully evaluated, no age-related adverse reactions were found. However, age-related adverse reactions cannot be ruled out in elderly patients with concurrent diseases or taking other drugs concomitantly.
10. Treatment in case of overdose
1) Overdosage of this drug alone generally resulted in a mild course. Symptoms of overdose have included nausea, vomiting, seizures, asymptomatic arrhythmias (including nodal rhythms and ventricular arrhythmias) or cardiovascular disorders ranging from electrocardiographic changes indicative of QTc prolongation to cardiac arrest (including very rare cases of torsade de pointes), pulmonary dysfunction, and signs of CNS changes ranging from agitation to coma. Deaths due to overdose of this drug alone are very rare. Monitoring of the heart and vital signs along with routine symptomatic and supportive care is recommended. No specific antidote is known.
Forced diuresis, renal dialysis, hemoperfusion, and exchange transfusion may not be beneficial. Activated charcoal, which can be used with sorbitol, may be equally or more effective than vomiting or gastric lavage. When managing overdose, the involvement of other drugs must be taken into consideration. If the patient is currently taking this medication or has recently taken this medication and has taken an overdose of a tricyclic antidepressant, extended close medical observation may be necessary.
11. Pharmaceutical equivalence test information
A. The test drug Fluoxetine Hydrochloride Capsule 20 mg (HLB Pharmaceutical Co., Ltd.) and the control drug Furozac Capsule 20 mg (Fluoxetine Hydrochloride) [Lilli Korea Ltd.] were administered orally once on an empty stomach to healthy adults in a 2x2 crossover test. As a result, blood fluoxetine was measured in 30 people. The comparative evaluation values (AUCt, Cmax) were log-transformed. When subjected to statistical processing, the 90% confidence interval of the mean difference was within log0.8 to log1.25, proving biological equivalence.
- Table: Refer to manual -
B. In accordance with Article 7, Paragraph 2 of the Pharmaceutical Equivalence Test Standards, the test drug Fluoxetine Hydrochloride Capsule 10 mg [HLB Pharmaceutical Co., Ltd.] submitted comparative dissolution test data with the reference drug Fluoxetine Hydrochloride Capsule 20 mg [HLB Pharmaceutical Co., Ltd.], and the dissolution pattern was equivalent to that of the reference drug. Accordingly, bioequivalence was proven with the relevant data.
12. Others
1) Laboratory tests: There are no particularly recommended tests.
2) Carcinogenicity, mutagenicity, impairment of fertility: No carcinogenicity was found when administered to rats and mice for 2 years at doses of 10mg/kg/day and 12mg/kg/day, which are 1.2 and 0.7 times (per mg/m2) of the recommended maximum human dose (80mg). Fluoxetine and norfluoxetine did not show genotoxicity in bacterial mutation tests, DNA repair tests in cultured rat hepatocytes, lymphoma tests in mice, and sister chromatid exchange tests using Chinese hamster bone marrow cells. In two studies in which fluoxetine was administered to adult rats at doses of 7.5 mg/kg/day and 12.5 mg/kg/day (approximately 0.9 and 1.5 times the maximum recommended human dose per mg/m2), fluoxetine did not affect fertility. However, when administered to juvenile rats, adverse reactions occurred in terms of fertility.
3) Toxicity in animal experiments: Phospholipids increased in some tissues of mice, rats, and dogs that received this drug long-term, and this was found to be reversible after stopping treatment. In animals, phospholipid accumulation has been observed with the use of many positive cationic drugs, including fenfluramine, imipramine, and ranitidine, but the significance of this effect in humans is unknown.
4) Limited to Western capsules
① This drug is a controlled-release capsule filled with enteric-coated granules, and the drug does not dissolve until the pH of the gastrointestinal tract reaches 5.5 or higher. Due to this enteric coating, the absorption of fluoxetine is delayed by 1 to 2 hours compared to the immediate-release formulation.
② When this drug is administered once a week, the difference between the peak and trough concentrations of fluoxetine and norfluoxetine in the blood is greater than when administered once a day. (Fluoxetine: 24% (once a day), 164% (once a week), Norfluoxetine: 17% (once a day), 43% (once a week)) Plasma concentrations do not necessarily correspond to clinical responses. When this drug is administered once a week, the peak concentration is within the range of the average concentration when 20 mg is administered once a day. The average trough concentration is 76% lower for fluoxetine and 47% lower for norfluoxetine than when administered at 20 mg once daily. The average steady-state concentration was proportional to the total dose administered for both once-daily and once-weekly administration. When administered once a week compared to once a day, the average steady-state concentration is lowered by about 50%. When changing to once-a-week administration the next day after administering 20mg once a day, the highest blood concentration when administering 90mg once a week reached almost 1.7 times the highest blood concentration when administering 20mg once a day. On the other hand, when the changes were made at intervals of one week, the highest concentration in the blood was similar. The average fluoxetine steady-state concentration also increased when the treatment was changed to once a week the next day. From a pharmacodynamic point of view, it is advisable to leave an interval of one week between the last dose of 20 mg once daily and the first dose of 90 mg once a week.
13. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 capsules/bottle
7. Period of use
24 months from date of manufacture
Product Updates
Total 7items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 7 | Lucetin Cap. | Precautions for use | 2024.03.27 | Lucetine Capsule_Permission change order (draft) and change comparison table.pdfFile under review |
| 6 | Lucetin Cap. | Lucetin capsule (precautions for use) | 2013.09.13 | HWPFluoxetine hydrochloride single agent (oral) unification adjustment (draft) - Jeongjeongsa |
| 5 | Lucetin Cap. | Lucetin capsule (precautions for use) | 0000.00.00 | HWPLucetin capsule_Precautions for use_Change instructions and preparation for change |
| 4 | Lucetin Cap. | Lucetin Capsule (Dosage, Precautions for Use) | 2013.05.03 | HWPLucetin Capsule_Change Instruction.hwp |
| 3 | Lucetin Cap. | Lucetin capsule (precautions for use) | 2011.07.11 | HWPPrecautions for using Lucetin Capsule.hwp |
| 2 | Lucetin Cap. | Lucetin capsule (precautions for use) | 2008.07.14 | HWPLucetin capsule (precautions for use) change (2008.07.14).hwp |
| 1 | Lucetin Cap. | Lucetin capsule (precautions for use) | 2007.05.16 | HWPLucetin capsule (precautions for use) change (2007.05.16).hwp |